Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    "Appendix Cancer" | "Fluorouracil"

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04158349
Recruitment Status : Not yet recruiting
First Posted : November 8, 2019
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
University of Utah

Brief Summary:
This study is a prospective, multi-center, open-label phase I trial designed to determine the maximun tolerated dose of IP oxaliplatin when given in combination with mFOLFIRI.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Appendiceal Cancer Peritoneal Carcinoma Drug: Oxaliplatin Drug: mFOLFIRI Phase 1

Detailed Description:

This study is a prospective, multi-center, open-label phase I trial designed to determine the MTD of IP oxaliplatin when given in combination with mFOLFIRI. This will be conducted according to a traditional 3+3 dose-escalation schedule and halted once MTD is established.

After consent and once deemed eligible for trial participation, patients will receive four cycles of study therapy. During therapy, patients will be monitored for dose-limiting toxicities and adverse events. After completion of all four cycles patients will be followed until resolution of any ongoing study treatment-related adverse events, initiation of alternative treatment, and survival.

Study drug treatment will be administered on day one of a 14-day cycle and the DLT evaluation period will be defined as the first three cycles of combination treatment (from cycle one day one to the last day of cycle three). The severity of AEs will be graded according to the NCI-CTCAE version 5.0 A standard 3+3 dose escalation design will be used to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) while ensuring the safety and tolerability of the treatment. The study will test three dose levels of oxaliplatin.

Dose Level 3 115 mg/m2 IP every 2 weeks Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 1 (95 mg/m2). Escalation will continue until DLT stopping rules are met or the highest dose level is reached.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This study is a prospective, multi-center, open-label phase I trial designed to determine the MTD of IP oxaliplatin when given in combination with mFOLFIRI. This will be conducted according to a traditional 3+3 dose-escalation schedule and halted once MTD is established.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous mFOLFIRI for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer
Estimated Study Start Date : January 30, 2020
Estimated Primary Completion Date : January 30, 2023
Estimated Study Completion Date : January 30, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Arm Intervention/treatment
Experimental: Dose Level 1
Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
Drug: Oxaliplatin
Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 1 (95 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Drug: mFOLFIRI
mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.

Experimental: Dose Level 2
Dose Level 2: 105 mg/m2 Oxaliplatin IP every 2 weeks
Drug: Oxaliplatin
Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 1 (95 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Drug: mFOLFIRI
mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.

Experimental: Dose Level 3
Dose Level 3:115 mg/m2 Oxaliplation IP every 2 weeks
Drug: Oxaliplatin
Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 1 (95 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Drug: mFOLFIRI
mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.




Primary Outcome Measures :
  1. Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with peritoneal carcinomatosis of colorectal or appendiceal origin [ Time Frame: One Cycle is 14 days. The DLT evaluation period will be defined as the first three cycles of combination treatment (from cycle one day one to the last day of cycle three (42days) ]
    The incidence of DLTs during the defined DLT period


Secondary Outcome Measures :
  1. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment and the IP catheter will be measured. [ Time Frame: up to 3 years ]
    To assess the safety and feasibility of IP oxaliplatin when administered with systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin.

  2. The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured. [ Time Frame: up to 3 years ]
    • Objective response rate (ORR) after four cycles of study therapy. ORR will be assessed by the number of patients obtaining a complete response plus the number of patients obtaining a partial response divided by the number of total response evaluable subjects.

  3. The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured. [ Time Frame: Up to 3 years ]
    • Overall survival (OS) will be assessed as the time from trial initiation until death by any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject aged ≥ 18 years.
  • Histopathologically or cytologically confirmed colon, rectal or appendiceal adenocarcinoma with synchronous or metachronous (defined as occurring > 6 months after initial diagnosis) peritoneal dissemination of disease. (Stage IV peritoneal-based disease only)
  • Patient has active, measurable disease as defined by RECIST 1.1 and assessed by either abdominal CT/MRI.
  • Patients must be willing and able as assessed the treating investigator to undergo placement of an IP catheter and a Port-A Cath, if not already present.
  • Patients must have known satisfactory cardiopulmonary function as assessed by the treating investigator.
  • ECOG Performance Status ≤ 2.
  • Adequate organ function as defined as:

    • Hematologic:

      • Absolute neutrophil count (ANC) > 1200/mm3
      • Platelet count > 100,000/mm3
    • Hepatic:

      • Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
      • AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN
    • Coagulation:

      • International normalized ratio (INR) ≤ 1.5
      • Patients who are therapeutically anticoagulated and whose antithrombotic treatment can be withheld for operation are eligible.
    • Renal:

      • BUN and serum creatinine within normal limits.
      • eGFR ≥50 mL/min/1.73m2 or creatinine clearance ≥50 mL/min by Cockcroft-Gault
  • Negative serum or urine pregnancy test at screening for women of childbearing potential.
  • Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last study treatment administration if the risk of conception exists.
  • Recovery to baseline or ≤ Grade 1 CTCAE v.5 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy.
  • Willing to return for follow-up.
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

Sensory neuropathy > grade 1 from prior therapy.

  • Known low or absent Dipyrimidine Dehydrogenase (DPD) activity.
  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
  • Patients with metastases outside the peritoneal cavity.
  • The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
    • Other clinically significant disorders that would preclude safe study participation.
  • Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.

    -Note: Patients on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

  • Known chronic hepatitis B virus (HBV) or hepatitis C virus infection with a detectable viral load.

    -Note: Patients with an undetectable HBV viral load on appropriate suppressive therapy are eligible. Patients with an undetectable HCV viral load on appropriate treatment are eligible.

  • Live vaccinations within 4 weeks of cycle one day one and while on trial.
  • Known prior severe hypersensitivity to platinum compounds, any of the investigational medication or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).
  • Subjects taking prohibited medications as described in Section 6.4.2. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment.

Layout table for additonal information
Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT04158349     History of Changes
Other Study ID Numbers: HCI126164
First Posted: November 8, 2019    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Peritoneal Neoplasms
Appendiceal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Abdominal Neoplasms
Peritoneal Diseases
Cecal Neoplasms
Cecal Diseases
Oxaliplatin
Antineoplastic Agents